CSIMarket
 
Illumina Inc   (NASDAQ: ILMN)
 

Illumina Inc's Customers Performance

ILMN



 
ILMN's Source of Revenues During the corresponding time, Illumina Inc recorded a revenue increase by 4.15 % year on year, sequentially revenue fell by -2.59 %. While revenue at the Illumina Inc 's corporate clients

• List of ILMN Customers




for the same period Illumina Inc recorded revenue increase by 4.15 % year on year, sequentially revenue fell by -2.59 %.

• List of ILMN Customers

Illumina Inc's Business Units
Product    251.99 % of total Revenue
Service    47.39 % of total Revenue
Sequencing    272.01 % of total Revenue
Consumables    220.55 % of total Revenue
Instruments    31.44 % of total Revenue
Microarray    27.37 % of total Revenue
United States and Canada    166.52 % of total Revenue
EMEA    94.95 % of total Revenue
China    14.79 % of total Revenue
Asia Pacific    23.12 % of total Revenue






Illumina Inc's Comment on Sales, Marketing and Customers



The company serves customers across multiple markets, including genomic research centers, academic institutions, government laboratories, hospitals, pharmaceutical companies, biotechnology companies, commercial molecular diagnostic laboratories, and consumer genomics companies. Its products support research and clinical applications by offering integrated sequencing and microarray systems, consumables, and analysis tools designed to accommodate various genomic complexities, price points, and throughput requirements. On June 24, 2024, the company completed the spin-off of GRAIL into a new public company, distributing shares to its stockholders while retaining a minority stake.





Illumina Inc’s Comment on Sales, Marketing and Customers


The company serves customers across multiple markets, including genomic research centers, academic institutions, government laboratories, hospitals, pharmaceutical companies, biotechnology companies, commercial molecular diagnostic laboratories, and consumer genomics companies. Its products support research and clinical applications by offering integrated sequencing and microarray systems, consumables, and analysis tools designed to accommodate various genomic complexities, price points, and throughput requirements. On June 24, 2024, the company completed the spin-off of GRAIL into a new public company, distributing shares to its stockholders while retaining a minority stake.








ILMN's vs. Customers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)



COMPANY NAME MARKET CAP REVENUES INCOME EMPLOYEES
Illumina Inc 36,342.46 4,538.00 895.00 1,280
Adaptive Biotechnologies Corporation 4,258.54 308.08 -63.99 624
Fulgent Genetics Inc 577.46 322.97 -85.47 1,344
Grail Inc 6,183.64 165.26 -391.59 910
Interpace Biosciences Inc 0.00 36.52 24.45 102
Personalis Inc 1,667.82 69.67 -107.18 260
SUBTOTAL 29,478.50 2,715.90 -1,460.27 9,080
1 more clients available

Sign in to see all corporate customers for Illumina Inc .

Sources: Illumina Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Illumina Inc’s corporate clients.
For your research, we’ve provided 9 tables on Illumina Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.